health care worldwide · fresenius kabi: products for the therapy and care of critically and...

Health Care Worldwide

Fresenius Group Company Presentation, Fresenius SE & Co. KGaA Corporate Communications © Copyright, 5 Aug 2011, page 2

Antibodies

The Health Care Group

- Dialysis Products - Dialysis Care - Extracorporeal

Therapies

- IV Drugs - Clinical Nutrition - Infusion Therapy - Medical Devices /

Transfusion Technology

- Operation and management of acute clinics and rehabilitation centers

- Planning, constructing and managing health care facilities


The History of Fresenius (1)

1462 Opening of the Hirsch pharmacy in Frankfurt/Main (Germany)

1912 Founding of the company Dr. E. Fresenius by the owner of the Hirsch pharmacy, Dr. E. Fresenius

1934 Relocation of the company to Bad Homburg

1966 Start of sale of other companies’ dialysis machines and dialyzers

1979 Start of production of Fresenius’ own dialysis machines

1981 Change of the company’s corporate form into a stock corporation

1983 Start of production of synthetic polysulfone fiber membranes used in dialysis applications

1986 Listing of Fresenius AG on the Frankfurt stock exchange

1996 Founding and listing of Fresenius Medical Care AG

on the Frankfurt and New York stock exchanges


The History of Fresenius (2)

1997 Start of production in one of Europe's most modern factories for infusion solutions in Friedberg (Germany)

1999 Founding of Fresenius Kabi

2001 Acquisition of Wittgensteiner Kliniken AG

2004 Fresenius Kabi expands its IV drug business

2005 Acquisition of HELIOS Kliniken GmbH

2006 Acquisition of Renal Care Group

2007 Conversion of Fresenius AG into a European Company (Fresenius SE)

2008 Acquisition of Dabur Pharma Ltd., India

2008 Acquisition of APP Pharmaceuticals, Inc. Fresenius Kabi enters the U.S. pharmaceuticals market and achieves a leading position in the global IV generics industry


Facts: Fresenius in 2011 (as of June 30, 2011)

- 142,933 employees (as of June 30, 2011)

- In more than 150 countries worldwide

- Subsidiaries in more than 70 countries

- Sales of €8 billion (2nd quarter of 2011)

- Operating income (EBIT) of €1.2 billion

(2nd quarter of 2011)

- 225,909 patients are being treated in 2,838 dialysis centers

owned by Fresenius Medical Care (as of June 30, 2011)


Uppsala, Sweden

Inukai, Japan

Port Elizabeth, South Africa

Ogden, USA

Friedberg, Germany

Schweinfurt, Germany

Wuxi, China

Buzen, Japan

Guadalajara, Mexiko

St. Wendel, Germany

Strategically Located Production Sites Worldwide

Reynosa, Mexiko


Fresenius Group - Worldwide Production Plants


Fresenius - Employees by Region (as of June 30, 2011)

North America

46,965 employees

33 %

Europe

69,763 employees

49 %

Asia Pacific

12,977 employees

9 %

Latin America

11,995 employees

8 % Africa

1,233 employees

1 %


FRESENIUS MEDICAL CARE


Fresenius Medical Care: Who are our patients?

- People with chronic kidney failure

- People with acute kidney failure

- People with high cholesterol

- People with immune diseases

- People with liver failure


Fresenius Medical Care: The World's Leading Renal Therapy Company

- The world's leading company for dialysis products and dialysis services

- Operations in more than 100 countries

- Treating 225,909 patients in 2,838 dialysis clincis

as of June 30, 2011 - Patient growth of 6% p.a. worldwide - Acting in an approximately US$69 billion dialysis market


Fresenius Medical Care in 2011 (as of June 30, 2011)

Sales: US$ 6.230 billion


Operating income (EBIT): US$ 955 million


Employees: 81,357

(as of June 30, 2011)


FRESENIUS KABI


for oncological and other critical diseases, anesthetics, anti-infectives and analgesics

Fresenius Kabi: Products for the therapy and care of critically and chronically ill patients in and outside the hospital - No. 1 in infusion therapy and clinical nutrition in Europe

- A leading supplier of I.V. generic drugs in the U.S. market

- Significant market positions in Latin America and Asia Pacific

I.V. Drugs Infusion Therapies Clinical Nutrition

Medical Devices / Transfusion Technology

- Surgery

- Emergency Medicine

- Intensive Care

- Surgery

- Emergency Medicine

- Intensive Care

- Hospital Wards

- Intensive Care

- Hospital Wards

- Nursing Homes

- Outpatient Care

Blood volume substitutes, infusion solutions

Parenteral and enteral nutrition

Infusion & nutrition pumps, infusion management systems, disposables / transfusion technology


Fresenius Kabi in 2011 (as of June 30, 2011)

Sales: €1.971 billion (2nd quarter of 2011) Operating income (EBIT): € 411 million (2nd quarter of 2011) Employees: 23,670 (as of June 30, 2011)


FRESENIUS HELIOS


Fresenius Helios: One of the leading private hospital operators in Germany

- Hospitals*: 63

- Beds*: more than 18,500

- Inpatient treatments*: approx. 600,000

- Employees*: more than 33,000

- Sales*: €2.520 billion

* as of December 31, 2010


Fresenius Helios in 2011 (as of June 30, 2011)

Sales: €1.293 billion (2nd quarter of 2011) Operating income (EBIT): €58 million (2nd quarter of 2011) Employees: 33,931 (as of June 30, 2011)


FRESENIUS VAMED


Fresenius Vamed: Technical services for health care facilities

- Project development

- Planning

- Project management

- Turnkey hospital projects

- Complete medical equipment

- Service and maintenance of medical-technical installations

- Facility management

- Technical management

- General management

- Project and management business in health care facilities

worldwide

- Realization of more than 500 health care projects in more

than 60 countries since its foundation in 1982


FRESENIUS VAMED in 2011 (as of June 30, 2011)

Sales: €313 million (2nd quarter 2011) EBIT: €12 million (2nd quarter 2011) Employees: 3,170 (as of June 30, 2011)


FRESENIUS BIOTECH


Development and Marketing of Biopharmaceuticals Business

Main Areas of Research

Therapeutic Areas

Approved Antibodies

Oncology Transplantation

Fresenius Biotech: Focus on Oncology and Transplantation

EpCAM positive carcinomas,

e.g., Malignant Ascites

Gastric Carcinoma

Ovarian Cancer et al.

Catumaxomab (Removab®)

Organ Transplantation

Stem Cell Transplantation

Anti T-lymphocyte globulin (ATG-Fresenius S®)

Thank you !

Back Up


Key Data of the Fresenius Shares

*Final Xetra quotations on the Frankfurt Stock Exchange

2010 2009

Number of Shares 162,450,090 161,315,376

Stock Exchange Quotation Ordinary Share* (€)

High 67.59 43.76

Low 41.80 27.69

Year-end quotation 62.75 43.45

Dividend per Ordinary Share in € 0.86 0.75


80

90

100

110

120

130

140

150

160

31.12.09 31.03.10 30.06.10 30.09.10 31.12.10

Fresenius Ordinary Share Fresenius Preference Share DAX

Relative Price Performance of Shares

Creating Benefit for the Public: Else Kröner-Fresenius Foundation


The Else Kröner-Fresenius Foundation – Its Origins

About the benefactress Else Kröner:

- Born in 1925 in Frankfurt, lost her father at the age of three

- After her father’s death, she lived in the household of Dr. E. Fresenius, owner of the Hirsch pharmacy in Frankfurt and of the company Fresenius, which he founded.

- Received practical training in the Hirsch pharmacy and subsequently decided to study pharmaceutics

- Inherited the pharmacy and company from Dr. Fresenius after his death in 1946 and took over responsibility for both

- Used the income earned from the company to safeguard its existence and growth

- The assets were to be used to the benefit of the general public.


The Else Kröner-Fresenius Foundation – Its Origins

The History of the Foundation:

- Founded on April 7, 1983

- With the foundation, Else Kröner intended to continue her life's work by focusing on the support of medical research projects and humanitarian causes.

- After her death on June 5, 1988, her assets were transferred to the foundation, where they now represent the majority of Fresenius' common stock.

- The administrative council decides how to use the income and the foundation's assets.

- There is no relation between the company Fresenius and the foundation.


The Else Kröner-Fresenius Foundation – Objectives and Activities

The Foundation's Tasks:

- Support of the medical sciences (especially in the field of research and treatment of diseases)

- Supports only research projects to the results of which the public has access

- Supports

- the training of physicians and other staff working in medical care

- accident victims and elderly care

- mentally or physically disabled persons

- Supports projects having application, analysis or development as a goal


The Else Kröner-Fresenius Foundation – Objectives and Activities

The Foundation's Activities:

- Until the end of 2009, support has been granted in more than 890 cases amounting to approximately €94 million.

- Scientific projects focusing on the following subjects have been supported:

- Training of physicians or other staff working in medical care

- Charity projects

- Transplantation

- Clinical nutrition and home care

- Fields of specialized medical interest

- Nephrology

- Dialysis technology

health care worldwide · fresenius kabi: products for the therapy and care of critically and...

Documents